Alucent Biomedical Revenue and Competitors

Location

$35.4M

Total Funding

Estimated Revenue & Valuation

  • Alucent Biomedical's estimated annual revenue is currently $3.6M per year.(i)
  • Alucent Biomedical's estimated revenue per employee is $125,500
  • Alucent Biomedical's total funding is $35.4M.

Employee Data

  • Alucent Biomedical has 29 Employees.(i)
  • Alucent Biomedical grew their employee count by 4% last year.

Alucent Biomedical's People

NameTitleEmail/Phone
1
President & CEOReveal Email/Phone
2
Chief Financial OfficerReveal Email/Phone
3
VP - Finance & AdministrationReveal Email/Phone
4
VP, Clinical AffairsReveal Email/Phone
5
VP Research & DevelopmentReveal Email/Phone
6
Plant ManagerReveal Email/Phone
7
Project Manager, Clinical AffairsReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$94.6M37728%N/AN/A
#2
$16.8M67-17%N/AN/A
#3
$485.4M19347%N/AN/A
#4
$43.7M17415%N/AN/A
#5
$75M19243%$12.8MN/A
#6
$6M24-8%N/AN/A
#7
$7.3M29-22%N/AN/A
#8
$38.4M1533%N/AN/A
#9
$174.4M6959%N/AN/A
#10
$6.8M27-34%N/AN/A
Add Company

What Is Alucent Biomedical?

Alucent Medical, Inc. is a privately-held biotechnology company, based in Salt Lake City, UT, developing a novel drug-device combination therapy, Natural Vascular Scaffolding (NVS) for patients with peripheral vascular disease.

keywords:N/A

$35.4M

Total Funding

29

Number of Employees

$3.6M

Revenue (est)

4%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Alucent Biomedical News

2022-04-13 - Alucent Biomedical Announces First Patient Enrolled in First In ...

Alucent Biomedical is a privately held company dedicated to developing and commercializing its breakthrough Natural Vascular Scaffolding (...

2022-04-13 - Alucent Biomedical anounces first patient enrolled in first-in ...

Alucent Biomedical anounces first patient enrolled in first-in-human natural vascular scaffolding clinical trial. 12th April 2022. 3. natural...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$5.9M29-17%N/A
#2
$7.3M29-22%N/A
#3
$5.1M29-12%N/A
#4
$4.1M290%N/A
#5
$7.5M290%N/A